WAYNE, PA — Teleflex Incorporated (NYSE: TFX) reported second quarter results that exceeded expectations and raised its full-year 2025 guidance following the successful acquisition of BIOTRONIK’s Vascular Intervention business.
Second quarter GAAP revenue grew 4.2% year-over-year to $780.9 million, with adjusted constant currency revenue up 1.0%. GAAP diluted earnings per share from continuing operations rose to $2.77, up from $1.69 in the same period last year. Adjusted diluted EPS increased to $3.73, compared to $3.42 in Q2 2024.
Chairman and CEO Liam Kelly credited the performance to strong operational execution and highlighted the strategic impact of the recent acquisition. “The addition of the Vascular Intervention business enhances our global presence in the cath lab and expands our footprint in the fast-growing peripheral intervention market,” he said.
Guidance Raised Across the Board
Teleflex now expects full-year GAAP revenue growth of 9.0% to 10.0%, up from its previous forecast of 1.28% to 2.28%. On an adjusted constant currency basis, the company projects 2025 revenue growth of 7.7% to 8.7%, revised upward from 1.0% to 2.0%. The revision is driven primarily by the BIOTRONIK acquisition, which is expected to contribute approximately $204 million in the second half of the year. Currency exchange is projected to add another 0.85% to topline growth.
Full-year GAAP EPS from continuing operations is now expected to range between $6.73 and $7.13, while adjusted EPS is projected between $13.90 and $14.30—up from earlier guidance of $13.20 to $13.60.
Balance Sheet and Dividend Update
As of June 29, Teleflex reported $283.9 million in total cash and equivalents, down from $327.7 million at year-end 2024. Net accounts receivable rose to $513.8 million, and inventories increased to $693.7 million. Depreciation and amortization costs for the first half of the year totaled $134.7 million, consistent with prior-year levels.
The company also announced a quarterly dividend of $0.34 per share, payable on September 15, 2025, to shareholders of record as of August 15, 2025.
Strategic Outlook
Teleflex continues to explore options for its planned separation of NewCo as part of a broader strategy to unlock shareholder value. With an expanded product portfolio and a strengthened position in interventional medicine, the company appears well-positioned to sustain momentum through the remainder of 2025.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.